Holdings
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
As of Jun 30, 2026, State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF reported 65 positions worth US$428M. Largest: Definium Therapeutics, Inc., Mbx Biosciences, Inc. and Alumis Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | 281K | US$13.2M | −35,565 | Jun 30, 2026 |
| Mbx Biosciences, Inc. | 211K | US$11.6M | +10,218 | Jun 30, 2026 |
| Alumis Inc. | 326K | US$9.17M | +102K | Jun 30, 2026 |
| Ataibeckley Inc. | 1.73M | US$9.11M | new | Jun 30, 2026 |
| Trevi Therapeutics, Inc. | 488K | US$9.1M | −6,539 | Jun 30, 2026 |
| Enliven Therapeutics, Inc. | 177K | US$8.97M | −15,601 | Jun 30, 2026 |
| Amylyx Pharmaceuticals, Inc. | 486K | US$8.72M | +90,308 | Jun 30, 2026 |
| Veradermics, Incorporated | 70,310 | US$8.64M | new | Jun 30, 2026 |
| Ligand Pharmaceuticals Incorporated | 26,334 | US$8.32M | −350 | Jun 30, 2026 |
| Nuvation Bio Inc. | 1.43M | US$8.11M | +141K | Jun 30, 2026 |